查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771313

电脑辅助药物发现市场：产业趋势及全球预测 - 依药物发现步骤、公司规模、治疗领域、主要地区（北美、欧洲、亚太地区及世界其他地区）

Computer Aided Drug Discovery Market: Industry Trends and Global Forecasts - Distribution by Drug Discovery Steps, Company Size, Therapeutic Area, and Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)
出版日期: | 出版商: Roots Analysis | 英文 290 Pages | 商品交期: 最快1-2个工作天内

价格

电脑辅助药物发现全球市场：概览

全球电脑辅助药物发现市场规模为 2,900万美元，预计在预测期内的年复合成长率为 15.6%。

市场区隔与机会分析依下列参数划分：

药物发现步骤

  • 标靶识别
  • 标靶验证
  • 目标化合物生成
  • 目标化合物到先导化合物（HTL）
  • 先导化合物最佳化

聚合物类型

  • 抗体
  • 蛋白质
  • 胜肽
  • 核酸
  • 载体

公司规模

  • 小型公司
  • 中型公司
  • 大型公司

治疗领域

  • 自体免疫疾病
  • 血液疾病
  • 心血管疾病
  • 胃肠道疾病
  • 荷尔蒙疾病
  • 爱滋病毒/爱滋病（HIV/A）感染性疾病
  • 传染病
  • 代谢性疾病
  • 精神疾病
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 肿瘤疾病
  • 呼吸系统疾病
  • 皮肤疾病
  • 泌尿系统疾病
  • 其他

赞助商类型

  • 产业内企业
  • 非行业进入者

主要地区

  • 北美（美国、加拿大）
  • 欧洲（义大利、德国、法国、西班牙、世界其他地区）
  • 亚太地区（中国、印度、日本）

全球电脑辅助药物发现市场：成长与趋势

随着时间的推移，药物发现的复杂性已经需求成长，尤其是大分子药物，它们本质上比传统的小分子药物更复杂。因此，看到製药合约製造/生物技术领域的整体研发支出增加。除了复杂性之外，药物发现过程在资本投入和时间方面都要求很高。因此，电脑辅助药物发现服务应运而生，成为解决此问题的潜在解决方案。

电脑辅助药物发现市场-IMG1

多年来，各种计算工具和服务应运而生，用于选择、建模、分析和最佳化潜在的候选先导化合物。电脑辅助药物发现提供者的预测能力已证明具有极大的优势，使研究人员能够避免在数百个生物标靶中随机筛选分子。此外，值得注意的是，据估计，这种方法可节省近35%的新药开发总成本，导致对大分子的更高效药物发现服务的需求增加。因此，提供像CADD这样的新型电脑辅助药物发现服务的公司现已成为製药业不可或缺的一部分。

全球电脑辅助药物发现市场：关键洞察

本报告深入探讨了全球电脑辅助药物发现市场的现状，并识别了该行业内的潜在成长机会。主要调查结果包括：

  • 超过90家公司积极参与为各种类型的生物製剂药物发现提供电脑辅助服务，其中约30家公司声称能够提供涵盖药物发现所有步骤的服务。
  • 其中约30家公司声称能够提供涵盖整个药物发现过程的服务。大多数公司提供基于结构的药物设计服务，致力于各种大分子（例如抗体、蛋白质和多肽）的早期药物发现。
  • 提供in silico服务的主要公司包括ChemPartner、Evotec、Jubilant Biosys、Schrodinger、Sygnature Discovery、WuXi AppTec等。
  • 超过30%的服务提供者为药物发现的所有步骤提供in silico服务。相较之下，基于标靶的药物发现步骤需要大量的实验支持。
  • 值得注意的是，在所有类型的抗体中，近60%的in silico服务针对单株抗体。其次是为各种类型的蛋白质和多肽提供in silico药物发现服务的公司。
  • in silico服务提供者以中小型企业为主，分布在不同地区，这些参与者采用了各种商业模式来满足客户不断变化的需求。
电脑辅助药物研发市场-IMG2
  • 该领域的多家公司稳步拓展自身能力，以增强其基于in silico的服务组合，并保持行业竞争力。
  • 人工智慧和云端平台等新型运算技术与in silico方法的结合，可能会彻底改变整个药物研发流程。
  • 服务提供者采用各种商业策略，以加速药物研发进度，提高产品成功率，同时继续提供显着的成本节约效益。
  • 由于对有效治疗药物的需求不断成长，以及各种生物製剂在广泛治疗领域的药物研发活动日益增多，预计未来该市场将持续成长。
  • 从长远来看，预计投资机会将在不同的地域、赞助商类型和服务提供者的公司规模之间实现充分的多样化。
电脑辅助药物发现市场-IMG3

电脑辅助药物发现市场参与者

  • BioDuro
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Abzena
  • BioNTech
  • Sygnature Discovery
  • ChemPartner
  • Sundia MediTech
  • Viva Biotech

本报告调查电脑辅助药物发现市场，提供市场概述，以及依药物发现步骤、公司规模、治疗领域和地区的趋势，和参与市场的公司简介。

目录

第1章 前言

第2章 执行摘要

第3章 引言

  • 章节概述
  • 药物发现与开发的时间线
  • in silico药物发现工具概述
  • in silico工具在药物发现过程中的应用
  • 在药物发现过程中使用in silico工具的优势
  • 实施in silico药物发现业务面临的挑战
  • 预测in silico药物发现业务外包将增加
  • 结论

第4章 市场格局

  • 章节概述
  • 聚合物in silico药物发现服务：公司列表行业
  • in silico药物发现服务：软体/技术列表

    第5章 关键洞见

    第6章 公司简介

    • 章节概述
    • 北美主要in silico服务供应商
      • BioDuro
      • Creative Biostructure
      • GenScript
      • LakePharma
    • 欧洲主要公司
      • Abzena
      • BioNTech
      • Sygnature Discovery
    • 亚太地区主要公司
      • ChemPartner
      • Sundia MediTech
      • Viva Biotech

    第7章 竞争分析

    • 章节概述
    • 关键参数
    • 研究方法
    • 竞争分析：北美in silico药物发现服务供应商
    • 竞争分析：欧洲in silico药物发现服务供应商
    • 竞争分析：亚太地区及世界其他地区in silico药物发现服务供应商

    第8章 关键机会领域

    • 章节概述
    • 关键假设与参数
    • 研究方法
    • 抗体
    • 胜肽类
    • 蛋白质类
    • 其他先进疗法

    第9章 新兴商业模式及策略

    • 章节概述
    • 关键假设与研究方法
    • in silico服务提供者：按涵盖的聚合物数量和药物发现步骤进行分析
    • 结论

    第10章 案例研究：小分子和聚合物药物发现过程的比较

    • 章节概述
    • 小分子与聚合物药物/治疗药物
    • 改进聚合物发现过程的方法

    第11章 研究见解

    第12章 成本降低分析

    第13章 市场预测

    • 章节概述
    • 预测研究方法与关键假设
    • 聚合物in silico药物发现服务市场：依药物发现步骤（2035）
    • 聚合物in silico药物发现服务市场：依聚合物类型（2035）
    • 聚合物in silico药物发现服务市场：依药物发现步骤（2035）
    • 聚合物in silico药物发现服务市场：依公司规模（～2035年）
    • 聚合物in silico药物发现服务市场：依治疗领域（～2035年）
    • 聚合物in silico药物发现服务市场：依赞助商类型（～2035年）
    • 聚合物in silico药物发现服务市场：依主要地区（～2035年）

第14章 in silico工具及药物研发的未来趋势

  • 章节概述
  • 由于潜在的成本和时间效益，未来药物研发活动的外包将会增加。
  • 技术进步可能会彻底改变目前的药物研发流程。
  • 结论

第15章 高层洞察

第16章 附录1：表格资料

第17章 附录2：公司与组织清单

第18章 附录3：药物研发的非计算方法

Product Code: RA100180

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: OVERVIEW

As per Roots Analysis, the global computer aided drug discovery market valued at USD 29 million in anticipated to grow at a CAGR of 15.6% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Drug Discovery Steps

  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

Type of Large Molecule

  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

Company Size

  • Small Companies
  • Mid-sized Companies
  • Large Companies

Therapeutic Area

  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • HIV / AIDS
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

Type of Sponsor

  • Industry Players
  • Non-Industry Players

Key Geographical Regions

  • North America (US and Canada)
  • Europe (Italy, Germany, France, Spain and Rest of Europe)
  • Asia-Pacific (China, India and Japan)

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: GROWTH AND TRENDS

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical contract manufacturing / biotechnology sector has been witnessed. In addition to the complexities involved, the drug discovery process is extremely demanding, both in terms of capital expenses and time. Consequently, computer-aided drug discovery services have emerged as a potential solution to the cause.

Computer Aided Drug Discovery Market - IMG1

Over the years, various computational tools and services have emerged, enabling the selection, modelling, analysis and optimization of potential lead candidates. The predictive power of computer aided drug discovery providers has proven to be extremely advantageous, allowing researchers to bypass the random screening of molecules across hundreds of biological targets. Moreover, it is worth highlighting that this approach has been estimated to save nearly 35% of the total cost involved in developing a new drug, resulting in growing demand for more efficient drug discovery services for large molecules. As a result, players offering novel in-silico drug discovery services, such as CADD, have now become an integral part of the pharmaceutical industry.

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: KEY INSIGHTS

The report delves into the current state of global computer aided drug discovery market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, around 30 players claim to have the capabilities to offer services for all steps of discovery.
  • Majority of the companies offer structure-based drug design focused on early-stage drug discovery of a range of large molecules, including antibodies, proteins and peptides.
  • Prominent examples of large companies that offer in-silico services include ChemPartner, Evotec, Jubilant Biosys, Schrodinger, Sygnature Discovery, WuXi AppTec.
  • More than 30% of the service providers offer in-silico services for all the steps of drug discovery; in contrast, target-based drug discovery steps require extensive experimental support.
  • Notably, nearly 60% of the in-silico services are offered for monoclonal antibodies among all types of antibodies; this is followed by companies offering in silico drug discovery services for different types of proteins and peptides.
  • Featuring the presence of small and mid-sized firms, the in-silico service provider landscape is well distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients.
Computer Aided Drug Discovery Market - IMG2
  • Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in-silico-based service portfolios and maintain a competitive edge in this industry.
  • The integration of novel computational techniques, such as artificial intelligence and cloud-based platforms, with in-silico approaches, is likely to revolutionize the overall drug discovery process.
  • Service providers are adopting various business strategies in order to continue providing significant cost saving advantages, along with expediting discovery timelines and improving product success.
  • Driven by the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutic areas, the market is expected to witness sustained growth in future.
  • In the long-term, the projected opportunity is anticipated to be well distributed across various geographies, type of sponsors and company sizes of service providers.
Computer Aided Drug Discovery Market - IMG3

Example Players in the Computer Aided Drug Discovery Market

  • BioDuro
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Abzena
  • BioNTech
  • Sygnature Discovery
  • ChemPartner
  • Sundia MediTech
  • Viva Biotech

PRIMARY RESEARCH OVERVIEW

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

  • Founder and Chief Executive Officer, Company A
  • Chief Executive Officer and Chief Technical Officer, Company B
  • Senior Vice President, Drug Discovery, Company C
  • Founder, Company D

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global computer aided drug discovery market, focusing on key market segments, including [A] drug discovery steps, [B] type of large molecule, [C] company size, [D] therapeutic area, [E] type of sponsor and [F] key geographical regions.
  • Market Landscape: A comprehensive evaluation of companies offering in silico drug discovery services for large molecules, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of business model used, [E] number of drug discovery step(s) for which the company offers services involving the use of in silico approaches, [F] type of large molecules(s) handled, [G] type of in silico approach used, [H] type of in silico service(s) offered and [I] type of clientele served.
  • Key Insights: An insightful analysis of contemporary market trends that have been depicted using four schematic representations, including [A] an analysis of the industry players engaged in this domain, distributed based on the location of their company size and respective headquarters, [B] an analysis of in silico service providers, [C] a detailed analysis, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
  • Company Profiles: In-depth profiles of companies that offer in silico drug discovery services, focusing on [A] company overview, [B] financial information (if available), [C] in silico-based service(s) portfolio and [D] recent developments and an informed future outlook.
  • Company Competitiveness Analysis: A comprehensive competitive analysis of at-home self-testing kit manufacturers, examining factors, such as strength of their respective service portfolios, taking into consideration the [A] experience of a service provider, [B] number of drug discovery services offered and [C] number of large molecules, for which the aforementioned services are offered.
  • Key Opportunity Areas: In-depth analysis of current opportunity within in-silico drug discovery services market, comparing the number of pipeline products and current market size based on [A] type of large molecule and the availability and capabilities of affiliated in silico drug discovery service providers.
  • Emerging Business Models and Strategies: A comprehensive discussion on the various business strategies that can be adopted by in-silico drug discovery service providers, based on [A] the different types of large molecules handled and [B] the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
  • Cost Saving Analysis: A detailed analysis focusing on the cost saving potential associated with the use of in-silico approaches in the drug discovery process.
  • Case Study: A detailed discussion on the key challenges associated with the [A] discovery and production of large molecules, [B] affiliated product development timelines, and [C] manufacturing protocols, with those of small molecule drugs.
  • Survey Insights: Comprehensive insights from an industry-wide survey, highlighting inputs solicited from various experts who are directly or indirectly engaged in providing in silico services for discovery of large molecule drugs.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Drug Discovery and Development Timelines
  • 3.3. Overview of In Silico Drug Discovery Tools
    • 3.3.1. Historical Evolution of the In Silico Approach
    • 3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
    • 3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development
  • 3.4. Applications of In Silico Tools in the Drug Discovery Process
    • 3.4.1. Target Identification
      • 3.4.1.1. Chemoinformatics-based Tools
      • 3.4.1.2. Network-based Drug Discovery
      • 3.4.1.3. Computational Platforms and Interaction Repositories
    • 3.4.2. Target Validation
    • 3.4.3. Hit Generation
      • 3.4.3.1. High-Throughput Screening
      • 3.4.3.2. Fragment Based Screening
      • 3.4.3.3. Virtual Screening
    • 3.4.4. Hit-to-Lead
      • 3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
      • 3.4.4.2. Other Novel Approaches
    • 3.4.5. Lead Optimization
      • 3.4.5.1. Pharmacophore Modeling
      • 3.4.5.2. Docking
      • 3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)
      • 3.4.5.4. Molecular Modeling
  • 3.5. Advantages of using In Silico Tools for Drug Discovery Operations
  • 3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations
  • 3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
  • 3.8. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Company Size and Location of Headquarters
    • 4.2.5. Analysis by Type of Business Model
    • 4.2.6. Analysis by Drug Discovery Steps
    • 4.2.7. Analysis by Type of Large Molecule
      • 4.2.7.1. Analysis by Type of Antibody
      • 4.2.7.2. Analysis by Type of Protein
    • 4.2.8. Analysis by Type of In Silico Approach Used
    • 4.2.9. Analysis by Types of In Silico Services Offered
    • 4.2.10. Analysis by Type of Clientele
  • 4.3. In Silico Drug Discovery Services: List of Software / Technologies

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
  • 5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
  • 5.4. World Map Representation: Regional Analysis of Outsourcing Activity
  • 5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Key In Silico Service Providers Based in North America
    • 6.2.1. BioDuro
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Funding and Investment Information
      • 6.2.1.3. In Silico-based Service Portfolio
      • 6.2.1.4. Recent Developments and Future Outlook
      • 6.2.1.5. Peer Group Benchmark Comparison
    • 6.2.2. Creative Biostructure
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Funding and Investment Information
      • 6.2.2.3. In Silico-based Service Portfolio
      • 6.2.2.4. Recent Developments and Future Outlook
      • 6.2.2.5. Peer Group Benchmark Comparison
    • 6.2.3. GenScript
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Funding and Investment Information
      • 6.2.3.3. In Silico-based Service Portfolio
      • 6.2.3.4. Recent Developments and Future Outlook
      • 6.2.3.5. Peer Group Benchmark Comparison
    • 6.2.4. LakePharma
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Funding and Investment Information
      • 6.2.4.3. In Silico-based Service Portfolio
      • 6.2.4.4. Recent Developments and Future Outlook
      • 6.2.4.5. Peer Group Benchmark Comparison
  • 6.3. Leading Players Based in Europe
    • 6.3.1. Abzena
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Funding and Investment Information
      • 6.3.1.3. In Silico-based Service Portfolio
      • 6.3.1.4. Recent Developments and Future Outlook
      • 6.3.1.5. Peer Group Benchmark Comparison
    • 6.3.2. BioNTech
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Funding and Investment Information
      • 6.3.2.3. Recent Developments and Future Outlook
      • 6.3.2.4. Peer Group Benchmark Comparison
    • 6.3.3. Sygnature Discovery
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Funding and Investment Information
      • 6.3.3.3. In Silico-based Service Portfolio
      • 6.3.3.4. Recent Developments and Future Outlook
      • 6.3.3.5. Peer Group Benchmark Comparison
  • 6.4. Leading Players Based in Asia-Pacific
    • 6.4.1. ChemPartner
      • 6.4.1.1. Company Overview
      • 6.4.1.2. In Silico-based Service Portfolio
      • 6.4.1.3. Recent Developments and Future Outlook
      • 6.4.1.4. Peer Group Benchmark Comparison
    • 6.4.2. Sundia MediTech
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Funding and Investment Information
      • 6.4.2.3. In Silico-based Service Portfolio
      • 6.4.2.4. Recent Development and Future Outlook
      • 6.4.2.5. Peer Group Benchmark Comparison
    • 6.4.3. Viva Biotech
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Funding and Investment Information
      • 6.4.3.3. In Silico-based Service Portfolio
      • 6.4.3.4. Recent Development and Future Outlook
      • 6.4.3.5. Peer Group Benchmark Comparison

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Key Parameters
  • 7.3. Methodology
  • 7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
  • 7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
  • 7.6. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World

8. KEY OPPORTUNITY AREAS

  • 8.1. Chapter Overview
  • 8.2. Key Assumptions and Parameters
  • 8.3. Methodology
  • 8.4. Antibodies
    • 8.4.1. Developer Landscape
      • 8.4.1.1. Number of Pipeline Molecules
      • 8.4.1.2. Affiliated Market Size and Growth Rate
    • 8.4.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.5. Peptides
    • 8.5.1. Developer Landscape
      • 8.5.1.1. Number of Pipeline Molecules
      • 8.5.1.2. Affiliated Market Size and Growth Rate
    • 8.5.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.6. Proteins
    • 8.6.1. Developer Landscape
      • 8.6.1.1. Number of Pipeline Molecules
      • 8.6.1.2. Affiliated Market Size and Growth Rate
    • 8.6.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.7. Other Advanced Therapies
    • 8.7.1. Developer Landscape
      • 8.7.1.1. Number of Pipeline Molecules
      • 8.7.1.2. Affiliated Market Size and Growth Rate
    • 8.7.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

9. EMERGING BUSINESS MODELS AND STRATEGIES

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
    • 9.3.1. Strategies for Short Term Success
    • 9.3.2. Strategies for Long Term Success
  • 9.4. Concluding Remarks

10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES

  • 10.1. Chapter Overview
  • 10.2. Small Molecule and Large Molecule Drugs / Therapies
    • 10.2.1. Comparison of Key Specifications
    • 10.2.2. Comparison of Manufacturing Processes
    • 10.2.3. Comparison of Drug Discovery Processes
  • 10.3. Approaches to Improve Discovery Process of Large Molecules

11. SURVEY INSIGHTS

  • 11.1. Chapter Overview
  • 11.2. Overview of Respondents
    • 11.2.1. Designation of Respondents
  • 11.3. Survey Insights
    • 11.3.1. Drug Discovery Steps
    • 11.3.2. Type of Molecules Handled
    • 11.3.3. In Silico Drug Design Focused Service Portfolio
    • 11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
    • 11.3.5. Current Market Opportunity
    • 11.3.6. Likely Growth Rate
    • 11.3.7. Cost Saving Potential of the In Silico Approach

12. COST SAVING ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions
  • 12.3. Methodology
  • 12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035
  • 12.5. Concluding Remarks

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035
    • 13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, Till 2035
      • 13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, Till 2035
      • 13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, Till 2035
      • 13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, Till 2035
      • 13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, Till 2035
      • 13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, Till 2035
    • 13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, Till 2035
      • 13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, Till 2035
      • 13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, Till 2035
      • 13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, Till 2035
      • 13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, Till 2035
      • 13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, Till 2035
    • 13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, Till 2035
      • 13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, Till 2035
      • 13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, Till 2035
      • 13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, Till 2035
    • 13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, Till 2035
      • 13.3.4.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, Till 2035
      • 13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, Till 2035
      • 13.3.4.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, Till 2035
      • 13.3.4.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, Till 2035
      • 13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, Till 2035
      • 13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), Till 2035
      • 13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, Till 2035
      • 13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, Till 2035
      • 13.3.4.9. In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, Till 2035
      • 13.3.4.10. In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, Till 2035
      • 13.3.4.11. In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, Till 2035
      • 13.3.4.12. In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders Till 2035
      • 13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, Till 2035
      • 13.3.4.14. In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, Till 2035
      • 13.3.4.15. In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, Till 2035
      • 13.3.4.16. In Silico Drug Discovery Services Market for Large Molecules: Share of Others, Till 2035
    • 13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, Till 2035
      • 13.3.5.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, Till 2035
      • 13.3.5.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, Till 2035
    • 13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, Till 2035
      • 13.3.6.1. In Silico Drug Discovery Services Market for Large Molecules: Share of North America, Till 2035
        • 13.3.6.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of US, Till 2035
        • 13.3.6.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, Till 2035
      • 13.3.6.2. In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, Till 2035
        • 13.3.6.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, Till 2035
        • 13.3.6.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share in France, Till 2035
        • 13.3.6.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, Till 2035
        • 13.3.6.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, Till 2035
        • 13.3.6.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, Till 2035
        • 13.3.6.2.6. In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, Till 2035
      • 13.3.6.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, Till 2035
        • 13.3.6.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share in China, Till 2035
        • 13.3.6.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share in India, Till 2035
        • 13.3.6.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, Till 2035

14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY

  • 14.1. Chapter Overview
  • 14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
  • 14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
    • 14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve Overall Efficiency and Productivity
    • 14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
    • 14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
  • 14.4. Concluding Remarks

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Company A
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Founder and Chief Executive Officer
  • 15.3. Company B
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Chief Executive Officer and Chief Technical Officer
  • 15.4. Company C
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Senior Vice President, Drug Discovery
  • 15.5. Company D
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Founder

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

List of Tables

  • Table 4.1. In Silico Drug Discovery Service Providers for Large Molecules: List of Industry Players
  • Table 4.2. In Silico Drug Discovery Services for Large Molecules: Information on Drug Discovery Steps
  • Table 4.3. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of In Silico Approach
  • Table 4.4. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of Clientele
  • Table 4.5. In Silico Drug Discovery Services for Large Molecules: Information on Type of Large Molecule
  • Table 4.6. In Silico Drug Discovery Services for Large Molecules: Information on In Silico-based Service Offerings
  • Table 4.7. In Silico Drug Discovery Services for Large Molecules: Additional Information
  • Table 4.8. In Silico Drug Discovery Services: List of Software / Technologies
  • Table 6.1. In Silico Service Providers: List of Companies Profiled
  • Table 6.2. BioDuro: Key Highlights
  • Table 6.3. BioDuro: List of Funding Instances and Investors
  • Table 6.4. BioDuro: Recent Developments and Future Outlook
  • Table 6.5. Creative Biostructure: Key Highlights
  • Table 6.6. Creative Biostructure: List of Funding Instances and Investors
  • Table 6.7. Creative Biostructure: Recent Developments and Future Outlook
  • Table 6.8. GenScript: Key Highlights
  • Table 6.9. GenScript: List of Funding Instances and Investors
  • Table 6.10. GenScript: Recent Developments and Future Outlook
  • Table 6.11. LakePharma: Key Highlights
  • Table 6.12. LakePharma: List of Funding Instances and Investors
  • Table 6.13. LakePharma: Recent Developments and Future Outlook
  • Table 6.14. Abzena: Key Highlights
  • Table 6.15. Abzena: List of Funding Instances and Investors
  • Table 6.16. Abzena: Recent Developments and Future Outlook
  • Table 6.17. BioNTech: Key Highlights
  • Table 6.18. BioNTech: List of Funding Instances and Investors
  • Table 6.19. BioNTech: Recent Developments and Future Outlook
  • Table 6.20. Sygnature Discovery: Key Highlights
  • Table 6.21. Sygnature Discovery: List of Funding Instances and Investors
  • Table 6.22. Sygnature Discovery: Recent Developments and Future Outlook
  • Table 6.23. ChemPartner: Key Highlights
  • Table 6.24. ChemPartner: Recent Developments and Future Outlook
  • Table 6.25. Sundia MediTech: Key Highlights
  • Table 6.26. Sundia MediTech: List of Funding Instances and Investors
  • Table 6.27. Sundia MediTech: Recent Developments and Future Outlook
  • Table 6.28. Viva Biotech: Key Highlights
  • Table 6.29. Viva Biotech: List of Funding Instances and Investors
  • Table 6.30. Viva Biotech: Recent Developments and Future Outlook
  • Table 10.1. Comparison of Strengths and Weaknesses of Small Molecules and Large Molecules
  • Table 10.2. Comparison of Development Characteristics of Small Molecules and Large Molecules
  • Table 10.3. Challenges in the Discovery of Different Types of Large Molecules
  • Table 11.1. Survey Insights: Overview of Respondents
  • Table 11.2. Survey Insights: Designation and Seniority Levels
  • Table 11.3. Survey Insights: Drug Discovery Steps Covered in Service Portfolio
  • Table 11.4. Survey Insights: Expertise Related to Different Types of Molecules
  • Table 11.5. Survey Insights: In Silico Drug Discovery Focused Service Portfolio
  • Table 11.6 Survey Insights: Other In Silico Services Offered
  • Table 11.7. Survey Insights: Likely Adoption of In Silico Tools for Large Molecule Drug Discovery
  • Table 11.8. Survey Insights: Opinions on Current Market Opportunity
  • Table 11.8. Survey Insights: Opinions on Likely Growth Rate
  • Table 11.9. Survey Insights: Opinions on Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
  • Table 12.1. Likely Cost Reduction using In Silico Services for Large Molecules and Small Molecules
  • Table 12.2 Drug Discovery Steps: Key Parameters
  • Table 14.1. Companies Offering Artificial Intelligence and In Silico Services
  • Table 14.2. Companies Offering Cloud Computing Platforms and In Silico Services
  • Table 15.1. ProSciens: Company Snapshot
  • Table 15.2. Conifer Point Pharmaceuticals: Company Snapshot
  • Table 16.1. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Year of Establishment
  • Table 16.2. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Company Size
  • Table 16.3. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Location of Headquarters
  • Table 16.4. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Business Model
  • Table 16.5. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Drug Discovery Steps
  • Table 16.6. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Large Molecule
  • Table 16.7. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Antibody
  • Table 16.8. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Protein
  • Table 16.9. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Designing Approach Used
  • Table 16.10. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by In Silico Service Offering
  • Table 16.11. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Clientele
  • Table 16.12. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
  • Table 16.13. World Map Representation: Regional Analysis of Outsourcing Activity
  • Table 16.14. Grid Representation: Distribution by Type of Large Molecule and Designing Approach
  • Table 16.15. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval
  • Table 16.16. Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Table 16.17. Survey Insights: Distribution of Respondents by Employee Size
  • Table 16.18. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
  • Table 16.19. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Table 16.20. Survey Insights: Distribution by Designation and Seniority Level of Respondents
  • Table 16.21. Survey Insights: Distribution by Drug Discovery Steps
  • Table 16.22. Survey Insights: Distribution by Type of Molecule
  • Table 16.23. Survey Insights: Distribution by In Silico-based Service Portfolio
  • Table 16.24. Survey Insights: Distribution by Likely Adoption of In Silico Tools
  • Table 16.25. Survey Insights: Distribution by Current Market Opportunity
  • Table 16.26. Survey Insights: Distribution by Likely Growth Rate
  • Table 16.27. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
  • Table 16.28. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035 (USD Billion)
  • Table 16.29. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035 (USD Million)
  • Table 16.30. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps
  • Table 16.31. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, Till 2035 (USD Million)
  • Table 16.32. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, Till 2035 (USD Million)
  • Table 16.33. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, Till 2035 (USD Million)
  • Table 16.34. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, Till 2035 (USD Million)
  • Table 16.35. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, Till 2035 (USD Million)
  • Table 16.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule
  • Table 16.37. In Silico Drug Discovery Services Market for Antibodies, Till 2035 (USD Million)
  • Table 16.38. In Silico Drug Discovery Services Market for Proteins, Till 2035 (USD Million)
  • Table 16.39. In Silico Drug Discovery Services Market for Peptides, Till 2035 (USD Million)
  • Table 16.40. In Silico Drug Discovery Services Market for Nucleic Acid, Till 2035 (USD Million)
  • Table 16.41. In Silico Drug Discovery Services Market for Vectors, Till 2035 (USD Million)
  • Table 16.42. In Silico Drug Discovery Services Market for Other Large Molecules, Till 2035 (USD Million)
  • Table 16.43. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size
  • Table 16.44. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, Till 2035 (USD Million)
  • Table 16.45. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, Till 2035 (USD Million)
  • Table 16.46. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, Till 2035 (USD Million)
  • Table 16.47. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Areas
  • Table 16.48. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, Till 2035 (USD Million)
  • Table 16.49. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, Till 2035 (USD Million)
  • Table 16.50. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, Till 2035 (USD Million)
  • Table 16.51. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, Till 2035 (USD Million)
  • Table 16.52. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, Till 2035 (USD Million)
  • Table 16.53. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, Till 2035 (USD Million)
  • Table 16.54. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, Till 2035 (USD Million)
  • Table 16.55. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, Till 2035 (USD Million)
  • Table 16.56. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, Till 2035 (USD Million)
  • Table 16.57. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, Till 2035 (USD Million)
  • Table 16.58. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, Till 2035 (USD Million)
  • Table 16.59. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, Till 2035 (USD Million)
  • Table 16.60. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, Till 2035 (USD Million)
  • Table 16.61. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, Till 2035 (USD Million)
  • Table 16.62. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, Till 2035 (USD Million)
  • Table 16.63. In Silico Drug Discovery Services Market for Large Molecules for Others, Till 2035 (USD Million)
  • Table 16.64. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor
  • Table 16.65. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, Till 2035 (USD Million)
  • Table 16.66. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, Till 2035 (USD Million)
  • Table 16.67. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions
  • Table 16.68. In Silico Drug Discovery Services Market for Large Molecules in North America, (USD Million)
  • Table 16.69. In Silico Drug Discovery Services Market for Large Molecules in the US, Till 2035 (USD Million)
  • Table 16.70. In Silico Drug Discovery Services Market for Large Molecules in Canada, Till 2035 (USD Million)
  • Table 16.71. In Silico Drug Discovery Services Market for Large Molecules in Europe, (USD Million)
  • Table 16.72. In Silico Drug Discovery Services Market for Large Molecules in Germany, Till 2035 (USD Million)
  • Table 16.73. In Silico Drug Discovery Services Market for Large Molecules in France, Till 2035 (USD Million)
  • Table 16.74. In Silico Drug Discovery Services Market for Large Molecules in the UK, Till 2035 (USD Million)
  • Table 16.75. In Silico Drug Discovery Services Market for Large Molecules in Italy, Till 2035 (USD Million)
  • Table 16.76. In Silico Drug Discovery Services Market for Large Molecules in Spain, Till 2035 (USD Million)
  • Table 16.77. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, Till 2035 (USD Million)
  • Table 16.78. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World (USD Million)
  • Table 16.79. In Silico Drug Discovery Services Market for Large Molecules in China, Till 2035 (USD Million)
  • Table 16.80. In Silico Drug Discovery Services Market for Large Molecules in India, Till 2035 (USD Million)
  • Table 16.81. In Silico Drug Discovery Services Market for Large Molecules in Japan, Till 2035 (USD Million)
  • Table 16.82. In Silico Drug Discovery Services Market for Large Molecules in Other Asian Countries, Till 2035 (USD Million)

List of Figures

  • Figure 3.1. Drug Discovery and Development Timeline
  • Figure 3.2. Historical Evolution of Computational Drug Discovery Approaches
  • Figure 3.3. Steps Involved in the Virtual Drug Discovery Process
  • Figure 3.4. Comparison of Traditional and In Silico Drug Discovery Approaches
  • Figure 3.5. Classification of In Silico Drug Discovery Approaches
  • Figure 3.6. Flowchart of the In Silico Drug Discovery Approach
  • Figure 3.7. In Silico Service Map for Drug Discovery Process
  • Figure 3.8. Advantages of using In Silico Drug Discovery Services
  • Figure 3.9. Types of Large Molecule Drugs
  • Figure 4.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
  • Figure 4.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
  • Figure 4.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
  • Figure 4.4 In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size and Location of Headquarters
  • Figure 4.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
  • Figure 4.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
  • Figure 4.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
  • Figure 4.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
  • Figure 4.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
  • Figure 4.10. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of In Silico Approach Used
  • Figure 4.11. In Silico Drug Discovery Services for Large Molecules: Distribution by Types of In Silico Services Offered
  • Figure 5.1. Logo Landscape: Distribution by Company Size and Location of Headquarters
  • Figure 5.2. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
  • Figure 5.3. World Map Representation: Regional Analysis of Outsourcing Activity
  • Figure 5.4. Grid Representation: Distribution by Type of Large Molecule, Designing Approach Used and Type of Clientele
  • Figure 6.1. BioDuro: In Silico-based Service Portfolio
  • Figure 6.2. BioDuro: Peer Group Benchmark Comparison
  • Figure 6.3. Creative Biostructure: In Silico-based Service Portfolio
  • Figure 6.4. Creative Biostructure: Peer Group Benchmark Comparison
  • Figure 6.5. GenScript: In Silico-based Service Portfolio
  • Figure 6.6. GenScript: Peer Group Benchmark Comparison
  • Figure 6.7. LakePharma: In Silico-based Service Portfolio
  • Figure 6.8. LakePharma: Peer Group Benchmark Comparison
  • Figure 6.9. Abzena: In Silico-based Service Portfolio
  • Figure 6.10. Abzena: Company Benchmarking Output
  • Figure 6.11. BioNTech: Peer Group Benchmark Comparison
  • Figure 6.12. Sygnature Discovery: In Silico-based Service Portfolio
  • Figure 6.13. Sygnature Discovery: Peer Group Benchmark Comparison
  • Figure 6.14. ChemPartner: In Silico-based Service Portfolio
  • Figure 6.15. ChemPartner: Peer Group Benchmark Comparison
  • Figure 6.16. Sundia MediTech: In Silico-based Service Portfolio
  • Figure 6.17. Sundia MediTech: Peer Group Benchmark Comparison
  • Figure 6.18. Viva Biotech: In Silico-based Service Portfolio
  • Figure 6.19. Viva Biotech: Peer Group Benchmark Comparison
  • Figure 7.1. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
  • Figure 7.2. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
  • Figure 7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
  • Figure 8.1. In Silico Drug Discovery Service Providers for Antibodies: 3D Bubble Representation
  • Figure 8.2. In Silico Drug Discovery Service Providers for Peptides: 3D Bubble Representation
  • Figure 8.3. In Silico Drug Discovery Service Providers for Proteins: 3D Bubble Representation
  • Figure 8.4. In Silico Drug Discovery Service Providers for Other Advanced Therapies: 3D Bubble Representation
  • Figure 9.1. In Silico Drug Discovery Service Providers: Popular Strategies or Business Models
  • Figure 10.1. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval
  • Figure 10.2. Small Molecules versus Large Molecules: Comparison of Key Characteristics
  • Figure 10.3. Small Molecules versus Large Molecules: Comparison of Manufacturing Process
  • Figure 11.1. Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Figure 11.2. Survey Insights: Distribution of Respondents by Company Size
  • Figure 11.3. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
  • Figure 11.4. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Figure 11.5. Survey Insights: Distribution by Designation and Seniority Level of Respondents
  • Figure 11.6. Survey Insights: Distribution by Drug Discovery Steps
  • Figure 11.7. Survey Insights: Distribution by Type of Molecules Handled
  • Figure 11.8. Survey Insights: Distribution by In Silico-based Service Portfolio
  • Figure 11.9. Survey Insights: Distribution by Likely Adoption of In Silico Tools
  • Figure 11.10. Survey Insights: Distribution by Current Market Opportunity
  • Figure 11.11. Survey Insights: Distribution by Likely Growth Rate
  • Figure 11.12. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
  • Figure 12.1. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery: Growth Scenarios
  • Figure 12.2. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035 (USD Billion)
  • Figure 13.1. Roots Analysis Forecasting Approach
  • Figure 13.2. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035 (USD Million)
  • Figure 13.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps (USD Million)
  • Figure 13.4. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, Till 2035 (USD Million)
  • Figure 13.5. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, Till 2035 (USD Million)
  • Figure 13.6. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, Till 2035 (USD Million)
  • Figure 13.7. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, Till 2035 (USD Million)
  • Figure 13.8. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, Till 2035 (USD Million)
  • Figure 13.9. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule (USD Million)
  • Figure 13.10. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, Till 2035 (USD Million)
  • Figure 13.11. In Silico Drug Discovery Services Market for Large Molecules for Proteins, Till 2035 (USD Million)
  • Figure 13.12. In Silico Drug Discovery Services Market for Large Molecules for Peptides, Till 2035 (USD Million)
  • Figure 13.13. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, Till 2035 (USD Million)
  • Figure 13.14. In Silico Drug Discovery Services Market for Large Molecules for Vectors, Till 2035 (USD Million)
  • Figure 13.15. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size (USD Million)
  • Figure 13.16. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, Till 2035 (USD Million)
  • Figure 13.17. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, Till 2035 (USD Million)
  • Figure 13.18. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, Till 2035 (USD Million)
  • Figure 13.19. In Silico Drug Discovery Services Market for Large Molecules: Market Attractiveness Analysis by Type of Therapeutic Area (USD Million)
  • Figure 13.20. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, Till 2035 (USD Million)
  • Figure 13.21. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, Till 2035 (USD Million)
  • Figure 13.22. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, Till 2035 (USD Million)
  • Figure 13.23. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, Till 2035 (USD Million)
  • Figure 13.24. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, Till 2035 (USD Million)
  • Figure 13.25. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, Till 2035 (USD Million)
  • Figure 13.26. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, Till 2035 (USD Million)
  • Figure 13.27. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, Till 2035 (USD Million)
  • Figure 13.28. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, Till 2035 (USD Million)
  • Figure 13.29. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, Till 2035 (USD Million)
  • Figure 13.30. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, Till 2035 (USD Million)
  • Figure 13.31. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, Till 2035 (USD Million)
  • Figure 13.32. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, Till 2035 (USD Million)
  • Figure 13.33. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, Till 2035 (USD Million)
  • Figure 13.34. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, Till 2035 (USD Million)
  • Figure 13.35. In Silico Drug Discovery Services Market for Large Molecules for Others, Till 2035 (USD Million)
  • Figure 13.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor (USD Million)
  • Figure 13.37. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, Till 2035 (USD Million)
  • Figure 13.38. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, Till 2035 (USD Million)
  • Figure 13.39. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions (USD Million)
  • Figure 13.40. In Silico Drug Discovery Services Market for Large Molecules in North America (USD Million)
  • Figure 13.41. In Silico Drug Discovery Services Market for Large Molecules in the US, Till 2035 (USD Million)
  • Figure 13.42. In Silico Drug Discovery Services Market for Large Molecules in Canada, Till 2035 (USD Million)
  • Figure 13.43. In Silico Drug Discovery Services Market for Large Molecules in Europe (USD Million)
  • Figure 13.44. In Silico Drug Discovery Services Market for Large Molecules in Germany, Till 2035 (USD Million)
  • Figure 13.45. In Silico Drug Discovery Services Market for Large Molecules in France, Till 2035 (USD Million)
  • Figure 13.46. In Silico Drug Discovery Services Market for Large Molecules in the UK, Till 2035 (USD Million)
  • Figure 13.47. In Silico Drug Discovery Services Market for Large Molecules in Italy, Till 2035 (USD Million)
  • Figure 13.48. In Silico Drug Discovery Services Market for Large Molecules in Spain, Till 2035 (USD Million)
  • Figure 13.49. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, Till 2035 (USD Million)
  • Figure 13.50. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World (USD Million)
  • Figure 13.51. In Silico Drug Discovery Services Market for Large Molecules in China, Till 2035 (USD Million)
  • Figure 13.52. In Silico Drug Discovery Services Market for Large Molecules in India, Till 2035 (USD Million)
  • Figure 13.53. In Silico Drug Discovery Services Market for Large Molecules in Japan, Till 2035 (USD Million)
  • Figure 14.1. Upcoming Trends in Drug Discovery: Future Growth Opportunities